PH12019502562B1 - N-substituted indole derivatives - Google Patents

N-substituted indole derivatives

Info

Publication number
PH12019502562B1
PH12019502562B1 PH1/2019/502562A PH12019502562A PH12019502562B1 PH 12019502562 B1 PH12019502562 B1 PH 12019502562B1 PH 12019502562 A PH12019502562 A PH 12019502562A PH 12019502562 B1 PH12019502562 B1 PH 12019502562B1
Authority
PH
Philippines
Prior art keywords
indole derivatives
substituted indole
formula
derivatives
prostaglandin
Prior art date
Application number
PH1/2019/502562A
Other languages
English (en)
Other versions
PH12019502562A1 (en
Inventor
Heinz Fretz
Isabelle Lyothier
Julien Pothier
Sylvia Richard-Bildstein
Thierry Sifferlen
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of PH12019502562A1 publication Critical patent/PH12019502562A1/en
Publication of PH12019502562B1 publication Critical patent/PH12019502562B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH1/2019/502562A 2017-05-18 2018-05-17 N-substituted indole derivatives PH12019502562B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2017062008 2017-05-18
PCT/EP2018/062865 WO2018210995A1 (en) 2017-05-18 2018-05-17 N-substituted indole derivatives

Publications (2)

Publication Number Publication Date
PH12019502562A1 PH12019502562A1 (en) 2020-07-20
PH12019502562B1 true PH12019502562B1 (en) 2024-06-14

Family

ID=62186481

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2019/502562A PH12019502562B1 (en) 2017-05-18 2018-05-17 N-substituted indole derivatives

Country Status (32)

Country Link
US (2) US20200069686A1 (enExample)
EP (1) EP3625224B1 (enExample)
JP (1) JP7065117B2 (enExample)
KR (1) KR102650756B1 (enExample)
CN (1) CN110621666A (enExample)
AR (1) AR111806A1 (enExample)
AU (1) AU2018269667B2 (enExample)
BR (1) BR112019024114A2 (enExample)
CA (1) CA3063637A1 (enExample)
CL (1) CL2019003257A1 (enExample)
CO (1) CO2019010804A2 (enExample)
CR (1) CR20190567A (enExample)
CY (1) CY1124528T1 (enExample)
DK (1) DK3625224T3 (enExample)
EA (1) EA039630B1 (enExample)
ES (1) ES2894124T3 (enExample)
HR (1) HRP20211532T1 (enExample)
HU (1) HUE056406T2 (enExample)
IL (1) IL270616B (enExample)
LT (1) LT3625224T (enExample)
MA (1) MA49127B1 (enExample)
MX (1) MX394108B (enExample)
PE (1) PE20191787A1 (enExample)
PH (1) PH12019502562B1 (enExample)
PL (1) PL3625224T3 (enExample)
PT (1) PT3625224T (enExample)
RS (1) RS62441B1 (enExample)
SG (1) SG11201908660RA (enExample)
SI (1) SI3625224T1 (enExample)
TW (1) TWI768043B (enExample)
UA (1) UA124748C2 (enExample)
WO (1) WO2018210995A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
AR111807A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2
HRP20211380T1 (hr) 2017-05-18 2021-11-26 Idorsia Pharmaceuticals Ltd Derivati pirimidina kao modulatori receptora pge2
TW201900180A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 嘧啶衍生物
AR111941A1 (es) 2017-05-18 2019-09-04 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
WO2021060281A1 (ja) * 2019-09-24 2021-04-01 Ａｇｃ株式会社 プロスタグランジンｅ２レセプターｅｐ２／ｅｐ４デュアルアンタゴニスト
CN115697317A (zh) * 2020-04-08 2023-02-03 株式会社AskAt Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用
TW202228674A (zh) 2020-11-13 2022-08-01 日商小野藥品工業股份有限公司 藉由併用ｅｐ４拮抗藥與免疫檢查點抑制物質而進行之癌症治療
WO2025229177A1 (en) 2024-05-02 2025-11-06 Idorsia Pharmaceuticals Ltd Crystalline forms of an n-substituted indole derivative

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003528144A (ja) 2000-03-24 2003-09-24 ファーマジーン ラボラトリーズ リミテッド 頭痛治療のためのプロスタノイドｅｐ４受容体アンタゴニストの使用およびそのアンタゴニストについてのアッセイ
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
BR0309305A (pt) 2002-04-12 2005-02-15 Pfizer Compostos de imidazol como agentes antiinflamatórios e analgésicos
AU2003216581A1 (en) 2002-04-12 2003-10-27 Pfizer Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
JP2006506327A (ja) 2002-05-23 2006-02-23 セラテクノロジーズ インコーポレイティド プロスタグランジンｅ２の受容体サブタイプｅｐ４のアンタゴニスト・ポリペプチド
CA2514220C (en) 2003-01-29 2012-02-28 Pharmagene Laboratories Limited Ep4 receptor antagonists
AR045507A1 (es) * 2003-08-26 2005-11-02 Teijin Pharma Ltd Derivados de pirrolo [3,2-d] pirimidina
ES2441206T3 (es) 2003-09-03 2014-02-03 Raqualia Pharma Inc. Compuestos de fenil o piridilamida como antagonistas de la prostaglandina E2
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
ES2327760T3 (es) 2004-05-04 2009-11-03 Raqualia Pharma Inc Compuestos de aril-heteroaril-amida ortosustituidos.
WO2005105732A1 (en) 2004-05-04 2005-11-10 Pfizer Japan Inc. Substituted methyl aryl or heteroaryl amide compounds
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
EP1885722B1 (en) 2005-05-19 2011-11-16 Merck Canada Inc. Quinoline derivatives as ep4 antagonists
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
JP5244091B2 (ja) 2006-04-24 2013-07-24 メルク カナダ インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのインドールアミド誘導体
EP2035376B1 (en) 2006-06-12 2014-08-27 Merck Canada Inc. Indoline amide derivatives as ep4 receptor ligands
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
AR061974A1 (es) 2006-07-14 2008-08-10 Novartis Ag Derivados de pirimidina como inhibidores de alk, composiciones farmaceuticas y procesos de obtencion
WO2008017164A1 (en) 2006-08-11 2008-02-14 Merck Frosst Canada Ltd. Thiophenecarboxamide derivatives as ep4 receptor ligands
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
JP5301469B2 (ja) 2007-02-26 2013-09-25 メルク カナダ インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体
CN101636385B (zh) 2007-03-26 2012-09-05 默克弗罗斯特加拿大有限公司 作为ep4受体拮抗剂的萘和喹啉磺酰脲衍生物
US8030489B2 (en) 2007-03-26 2011-10-04 Astellas Pharma Inc. Ornithine derivative
EP2014657A1 (de) 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine als Modulatoren des EP2-Rezeptors
EP2460787A1 (en) 2007-07-03 2012-06-06 Astellas Pharma Inc. Amide compounds and their use as PGE2 antagonists.
KR101612971B1 (ko) 2008-05-14 2016-04-15 아스테라스 세이야쿠 가부시키가이샤 아미드 화합물
CA2733247C (en) 2008-08-14 2018-04-03 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
WO2010032123A1 (en) 2008-09-19 2010-03-25 Biotechnology Research Corporation Limited Triterpenoid compounds and methods of use thereof
AU2009295308A1 (en) 2008-09-25 2010-04-01 Merck Canada Inc. Beta-carboline sulphonylurea derivatives as EP4 receptor antagonists
CN103003264B (zh) 2010-05-21 2014-08-06 切米利亚股份公司 嘧啶衍生物
LT2619182T (lt) 2010-09-21 2017-01-25 Eisai R&D Management Co., Ltd. Farmacinė kompozicija
WO2012043634A1 (ja) 2010-09-29 2012-04-05 株式会社エヌビィー健康研究所 ヒトプロスタグランジンｅ２受容体ｅｐ４に対する抗体
EP2649061B1 (en) 2010-12-10 2015-05-13 Rottapharm Biotech S.r.l. Pyridine amide derivatives as ep4 receptor antagonists
WO2012103071A2 (en) 2011-01-25 2012-08-02 Eisai R&D Management Co., Ltd. Compounds and compositions
AU2012230229A1 (en) 2011-03-24 2013-10-10 Noviga Research Ab Novel pyrimidine derivatives
KR101760164B1 (ko) 2011-07-04 2017-07-20 로타팜 바이오테크 에스.알.엘 Ep4 수용체 길항제로서 사이클릭 아민 유도체
EP2554662A1 (en) 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
US20150004175A1 (en) 2011-12-13 2015-01-01 Yale University Compositions and Methods for Reducing CTL Exhaustion
IN2014KN02601A (enExample) 2012-04-24 2015-05-08 Vertex Pharma
TWI572597B (zh) 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基－苯甲酸化合物
JO3296B1 (ar) 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2765128A1 (en) 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
TW201443004A (zh) 2013-02-15 2014-11-16 Lilly Co Eli 苯氧基乙氧基化合物
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物
RS57406B1 (sr) 2013-06-12 2018-09-28 Kaken Pharmaceutical Co Ltd Derivat 4-alkinil imidazola i lekovi koji ga sadrže kao aktivni sastojak
JP6417419B2 (ja) 2013-09-04 2018-11-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫調節剤として有用な化合物
EA030155B1 (ru) 2013-09-06 2018-06-29 Ауриген Дискавери Текнолоджиз Лимитед Производные 1,2,4-оксадиазола в качестве иммуномодуляторов
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
RS57306B1 (sr) 2013-10-17 2018-08-31 Vertex Pharma Inhibitori dnk-pk
WO2015094902A1 (en) 2013-12-17 2015-06-25 Eli Lilly And Company Phenoxyethyl cyclic amine derivatives and their activity as ep4 receptor modulators
HRP20190793T1 (hr) 2013-12-17 2019-06-28 Eli Lilly & Company Spojevi dimetilbenzojeve kiseline
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
SG11201609770TA (en) 2014-05-23 2016-12-29 Eisai R&D Man Co Ltd Combination therapies for the treatment of cancer
WO2016021742A1 (en) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
WO2016054807A1 (en) * 2014-10-10 2016-04-14 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
TWI852872B (zh) 2015-01-09 2024-08-11 日商小野藥品工業股份有限公司 三環性螺化合物之用途
EP3325490B1 (en) 2015-07-23 2019-12-18 Takeda Pharmaceutical Company Limited 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists
AU2016338679B2 (en) 2015-10-16 2021-05-06 Eisai R&D Management Co., Ltd. EP4 antagonists

Also Published As

Publication number Publication date
IL270616B (en) 2022-01-01
CL2019003257A1 (es) 2020-03-27
CY1124528T1 (el) 2022-07-22
TWI768043B (zh) 2022-06-21
RS62441B1 (sr) 2021-11-30
DK3625224T3 (da) 2021-11-08
SG11201908660RA (en) 2019-10-30
CR20190567A (es) 2020-02-10
CN110621666A (zh) 2019-12-27
KR102650756B1 (ko) 2024-03-22
MX2019013639A (es) 2020-01-21
US20230165859A1 (en) 2023-06-01
AU2018269667B2 (en) 2022-02-03
HRP20211532T1 (hr) 2022-01-07
PL3625224T3 (pl) 2022-01-10
AU2018269667A1 (en) 2019-10-24
US20200069686A1 (en) 2020-03-05
CA3063637A1 (en) 2018-11-22
MX394108B (es) 2025-03-21
JP7065117B2 (ja) 2022-05-11
MA49127B1 (fr) 2022-05-31
EP3625224B1 (en) 2021-08-04
SI3625224T1 (sl) 2021-11-30
PE20191787A1 (es) 2019-12-24
CO2019010804A2 (es) 2019-10-09
PT3625224T (pt) 2021-10-06
PH12019502562A1 (en) 2020-07-20
TW201900637A (zh) 2019-01-01
MA49127A (fr) 2021-05-26
LT3625224T (lt) 2021-10-25
KR20200006589A (ko) 2020-01-20
EA201992679A1 (ru) 2020-05-06
JP2020520359A (ja) 2020-07-09
AR111806A1 (es) 2019-08-21
EP3625224A1 (en) 2020-03-25
WO2018210995A1 (en) 2018-11-22
ES2894124T3 (es) 2022-02-11
HUE056406T2 (hu) 2022-02-28
UA124748C2 (uk) 2021-11-10
EA039630B1 (ru) 2022-02-18
BR112019024114A2 (pt) 2020-06-02

Similar Documents

Publication Publication Date Title
MY195888A (en) N-Substituted Indole Derivatives As Pge2 Receptor Modulators
PH12019502562B1 (en) N-substituted indole derivatives
MX2021004000A (es) Derivados de piperidina.
MY169986A (en) Benzimidazole-proline derivatives
MX389592B (es) Moduladores alostericos positivos del receptor m1 muscarinico
PH12022550338A1 (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
SA522431777B1 (ar) مشتقات ألفا -d- جالاكتو بيرانوسيد
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
PH12015502632A1 (en) Cxcr7 receptor modulators
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
PH12021553178A1 (en) Pyridin-3-yl derivatives
NZ763341A (en) Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
MX2020013291A (es) Derivados de piridinilo alcoxisustituido como antagonistas del receptor lpa1 y su uso en el tratamiento de la fibrosis.
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
NZ764004A (en) Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators
TN2018000175A1 (en) Indane derivatives as mglur7 modulators
MX2021004471A (es) Derivados de pirrolo-pididazina como moduladores alostéricos positivos del receptor muscarínico m1.
TH1901007033A (th) อนุพันธ์ของอินโดลที่ถูกแทนที่แบบ n
NZ764561A (en) Substituted azacycles as muscarinic m1 receptor positive allosteric modulators